Status:
COMPLETED
Diphenylcyclopropenone (DPCP) as a Depigmenting Therapy in Extensive Vitiligo
Lead Sponsor:
Ain Shams University
Conditions:
Vitiligo
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The aim of the present work is to evaluate the efficacy and safety of diphenylcyclopropenone (DPCP) as a depigmenting therapy in extensive Vitiligo.
Detailed Description
Depigmentation protocol: (Aghaei et al, 2005) * Substance used: DPCP (FLUKA, Sigma-Aldrich, Saint Louis, MO (Missouri), USA) 98% pure powder. * DPCP will be dissolved in acetone to obtain 2% solution...
Eligibility Criteria
Inclusion
- Adult patients of both genders ≥ 18 years.
- Vitiligo universalis patients with cosmetically unacceptable residual pigmentation.
- Extensive vitiligo vulgaris ≥ 50% body surface area (BSA) involvement with areas recalcitrant to repigmentation on exposed skin with consequent psychological impairment.
Exclusion
- Children.
- Early, localized, segmental or any vitiligo case responsive to repigmentation treatment.
- Pregnant and lactating females.
- Patients with history of any malignancy.
- Patients with active infectious or inflammatory dermatoses.
- Patients with a history of hypertrophic scars or keloids.
- Patients suffering from cardiac, hepatic or renal disorders.
Key Trial Info
Start Date :
January 17 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 30 2021
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04775979
Start Date
January 17 2021
End Date
August 30 2021
Last Update
April 11 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University hospitals faculty of medicine ain shams university
Cairo, Egypt